Nav: Home

Hepatitis B vaccination in preadolescents lowered the disease incidence rate in Catalonia

March 13, 2019

Introducing Hepatitis B vaccine in preadolescents meant a decline in the disease incidence rate by 52 % according to a study in which the University of Barcelona (UB) took part. The study analysed the efficiency and impact of the vaccination program set in Catalonia (Spain) twenty-one years ago. The results show that after introducing the program, the incidence rate in general population went from 2.5 per 100,000 people in 1991 to 1.2 per 100,000 people in 2014.

The study, published in the scientific journal Vaccine, counts on the participation of experts from the Research Group on Epidemiology, Prevention and Control of Communicable Diseases of the UB, the Public Health Agency of Catalonia and the Barcelona Public Health Agency, led by Professor Àngela Domínguez, from the Department of Medicine of the UB and the Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP, Institute of Health Carlos III).

Hepatitis B is a globally important viral disease due its morbidity, mortality and high chronicity in children. Chronicity increases the risk of cirrhosis and hepatocellular carcinoma, and patients with a chronic disease are permanent transmitters of the virus. In 1991, systematic vaccination for Hepatitis B was introduced in Catalonia in preadolescents. "So far, only risk groups were vaccinated, such as those working in the health sector or haemophiliac and haemodialytic patients. However, this type of vaccination was not enough to reduce the incidence", note the researchers.

An efficient program

Researchers studied retrospectively vaccinated and non-vaccinated cohorts, chosen according to their year of birth, as well as cases of Hepatitis B between 2000 and 2014 that were registered by the Sub-Directorate General for Epidemiological Surveillance and Public Health Emergency Response of the Public Health Agency of Catalonia. During that period, they notified about 388 cases of Hepatitis B infection, 232 in the non-vaccinated cohort and 156 in the vaccinated cohort.

The incidence rate was 4.1 per 100,000 people per year in the non-vaccinated group and 0.03 per 100,000 people per year in the vaccinated group. Therefore, the efficiency of the program was 99.30 % and the associated benefit to estimate the prevented fraction was of 64.56 %. According to the researchers, these results show that "efficiency and impact of the vaccination program for Hepatitis B in preadolescents are high, benefiting the community".

Vaccination in preadolescents was suspended in July 2014, when the first kids who had been vaccinated as children (vaccinated in 2002, aged one) reached preadolescence, so they did not need the vaccine again.
-end-


University of Barcelona

Related Hepatitis Articles:

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum M√ľnchen and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
How to cure more hepatitis C patients
The cost of cures for hepatitis C have been prohibitive, but experts who served on an NAS panel have a solution that will save more patients and incentivize drug innovation.
Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic.
Countries risk 'running out' of hepatitis C patients to treat, says World Hepatitis Alliance
The latest data on the global hepatitis C epidemic, released today at the World Hepatitis Summit in Sao Paulo, Brazil, reveal that most countries (especially high-income countries) are running out of patients to treat because of the low diagnosis rates worldwide.
Australia currently on track to eliminate hepatitis C by 2030, but challenges remain for hepatitis B
New data released at this year's World Hepatitis Summit in Sao Paulo, Brazil, shows that Australia is currently on track to eliminate hepatitis C thanks to its huge efforts to enable population-wide access to treatment.
More Hepatitis News and Hepatitis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.